Efficacy and safety of systemic isotretinoin treatment for moderate to severe acne (insights from the real-life clinical setting).
acne
antibiotics
isotretinoin
moderate acne
severe acne
systemic therapy
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
22
07
2020
revised:
02
09
2020
accepted:
23
09
2020
pubmed:
11
10
2020
medline:
15
5
2021
entrez:
10
10
2020
Statut:
ppublish
Résumé
Acne is a chronic inflammatory relapsing disease that affect predominantly adolescents, with scarring as a frequent sequele. Early and appropriate therapy allows better management of the disease, longer remission, scars risk reduction, and improvement of quality of life. According to therapeutic algorithm, systemic isotretinoin can be used in severe acne and also in moderate forms resistant to other systemic treatments. The aims of this real-life observational study were to determine and compare the effectiveness of isotretinoin evaluated by Global Acne Grading System and Acne Quality of Life in moderate and in severe acne, correlation between efficacy and cumulative dose of isotretinoin, tolerability, and recurrence rate. Moreover, the differences in efficacy and tolerability between male and female patients were compared. The treatment with systemic isotretinoin led to an improvement in acne severity and quality of life in all observed subjects.
Substances chimiques
Dermatologic Agents
0
Isotretinoin
EH28UP18IF
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14392Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Das S, Reynolds RV. Recent advances in acne pathogenesis: implications for therapy. Am J Clin Dermatol. 2014;15(6):479-488.
Oge LK, Broussard A, Marshall MD. Acne vulgaris: diagnosis and treatment. Am Fam Physician. 2019;100(8):475-484.
Thiboutot DM, Dréno B, Abanmi A, et al. Practical management of acne for clinicians: an international consensus from the global Alliance to improve outcomes in acne. J Am Acad Dermatol. 2018;78(2 suppl 1):S11-S23.
Rademaker M. Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us? Australas J Dermatol. 2013;54(3):157-162.
Rigopoulos D, Larios G, Katsambas AD. The role of isotretinoin in acne therapy: why not as first-line therapy? Facts and controversies. Clin Dermatol. 2010;28(1):24-30.
Veraldi S, Fabbrocini G, Cacciapuoti S, Masarà A. Terapia farmacologica. In Terapia dell'acne grave. Linee Guida SIDeMaST. https://www.pacinimedicina.it/wp-content/uploads/acne-grave-sidemast-38709.pdf. Accessed February 2020).
Tkachenko E, Singer S, Sharma P, Barbieri J, Mostaghimi A. US Food and Drug Administration reports of pregnancy and pregnancy-related adverse events associated with isotretinoin. JAMA Dermatol. 2019;155(10):1175-1179.
Droitcourt C, Poizeau F, Kerbrat S, et al. Isotretinoin and risk factors for suicide attempt: a population-based comprehensive case series and nested case-control study using 2010-2014 French health insurance data. J Eur Acad Dermatol Venereol. 2019;34(6):1293-1301. https://doi.org/10.1111/jdv.16005.
Droitcourt C, Nowak E, Rault C, et al. Risk of suicide attempt associated with isotretinoin: a nationwide cohort and nested case-time-control study. Int J Epidemiol. 2019;48(5):1623-1635.
Singer S, Tkachenko E, Sharma P, Barbieri JS, Mostaghimi A. Psychiatric adverse events in patients taking isotretinoin as reported in a Food and Drug Administration database from 1997 to 2017. JAMA Dermatol. 2019;155(10):1162-1166.
Doshi A, Zaheer A, Stiller MJ. A comparison of current acne grading systems and proposal of a novel system. Int J Dermatol. 1997;36(6):416-418.
Hawthorne G, Richardson J, Osborne R. The assessment of quality of life (AQoL) instrument: a psychometric measure of health-related quality of life. Qual Life Res. 1999;8(3):209-224.
Martin AR, Lookingbill DP, Botek A, Light J, Thiboutot D, Girman CJ. Health-related quality of life among patients with facial acne-assessment of a new acne-specific questionnaire. Clin Exp Dermatol. 2001;26(5):380-385.
Droitcourt C, Nowak E, Rault C, Happe A, Lw Natout B, Kerbrat S. Risk of suicide attempt associated with isotretinoin: a nationwide cohort and nested case-time-control study. Int J Epidemiol. 2019;48(5):1623-1635.
Barbieri JS, Shin DB, Wang S, Margolis DJ, Takeshita J. Association of race/ethnicity and sex with differences in health care use and treatment for acne. JAMA Dermatol. 2020;156(3):312-319.
Tolino E, Skroza N, Proietti I, Bernardini N, Balduzzi V, Anzalone A. Post acne scarring: which factors are involved? J Ital Dermatol Venereol. 2019;154(4):154-156.